|9 Months Ended|
Sep. 30, 2023
|Revenue from Contract with Customer [Abstract]|
NOTE 9 – REVENUES
Disaggregation of Net Revenues
The Company’s net product revenues are summarized below:
Gross-to-Net Sales Accruals
We record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary to the pharmaceutical industry.
Our provision for gross-to-net allowances was $2.5 million at September 30, 2023, $0.7 million of which was recorded as a reduction to accounts receivable and $1.8 million recorded as a component of accrued expenses.
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef